Icariin is the major active ingredient in Herba epimedii which is a commonly used Chinese herbal medicine for the treatment of osteoporosis. The present study aims to evaluate the osteoprotective effect of Icariin in glucocorticoid-induced osteoporosis in vivo and investigate the effect of Icariin on glucocorticoid-induced osteocyte apoptosis in vitro. A total of 48 female Sprague–Dawley rats were used. Glucocorticoid-induced osteoporosis was induced by daily injections of dexamethasone (0.1 mg/kg, daily, s.c.) for 60 days, whereas sham animals were injected daily with vehicle. At the end of the osteoporosis development period, osteoporotic rats were randomized to receive: vehicle (n = 8), Icariin (5,125 mg/kg, i.g.; n = 8), or alendronate (0.03 mg/kg, s.c.; n = 8) for 12 weeks. Sham animals were treated with vehicle for 12 weeks. At the beginning and at the end of treatments, animals were examined for bone mineral density. Serum bone-alkaline phosphatase and carboxy-terminal collagen cross links were measured. Primary osteocytes were isolated, and apoptosis was determined by trypan-blue assay. Interaction between Icariin and estrogen receptor and prosurvival signaling pathways activated by Icariin were also investigated. Icariin showed a comparable efficacy with alendronate in increasing bone mass. Icariin significantly increased bone-alkaline phosphatase (bone formation marker) and reduced carboxy-terminal collagen cross links (bone resorption marker). In vitro studies demonstrated that Icariin significantly prevented GC-induced apoptosis in osteocytes by activating ERK signaling via estrogen receptor. Our results suggest that Icariin might exert osteoprotective effect by maintaining osteocyte viability, thereby, regulating bone remodeling. Furthermore, our study provides preclinical evidence for the efficacy of Icariin for management of Glucocorticoid-induced osteoporosis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Liu, Y., Porta, A., Peng, X., Gengaro, K., Cunningham, E. B., Li, H., et al. (2004). Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k. Journal of Bone and Mineral Research, 19(3), 479–490.
Patschan, D., Loddenkemper, K., & Buttgereit, F. (2001). Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone, 29(6), 498–505.
Reid, I. R. (1997). Glucocorticoid osteoporosis–mechanisms and management. European Journal of Endocrinology, 137(3), 209–217.
Lukert, B. P., & Raisz, L. G. (1990). Glucocorticoid-induced osteoporosis: pathogenesis and management. Annals of Internal Medicine, 112(5), 352–364.
Feher, J. J., & Wasserman, R. H. (1979). Intestinal calcium-binding protein and calcium absorption in cortisol-treated chicks: effects of vitamin D3 and 1,25-dihydroxyvitamin D3. Endocrinology, 104(2), 547–551.
Manolagas, S. C. (2000). Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocrine Reviews, 21(2), 115–137.
Canalis, E., & Delany, A. M. (2002). Mechanisms of glucocorticoid action in bone. Annals of the New York Academy of Sciences, 966, 73–81.
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998). Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. The Journal of Clinical Investigation, 102(2), 274–282.
Bonewald, L. F., & Johnson, M. L. (2008). Osteocytes, mechanosensing and Wnt signaling. Bone, 42(4), 606–615.
Manolagas, S. C. (2000). Corticosteroids and fractures: a close encounter of the third cell kind. Journal of Bone and Mineral Research, 15(6), 1001–1005.
Kitase, Y., Barragan, L., Qing, H., Kondoh, S., Jiang, J. X., Johnson, M. L., et al. (2010). Mechanical induction of PGE2 in osteocytes blocks glucocorticoid-induced apoptosis through both the beta-catenin and PKA pathways. Journal of Bone and Mineral Research, 25(12), 2657–2668.
Adachi, J. D., Bensen, W. G., Bianchi, F., Cividino, A., Pillersdorf, S., Sebaldt, R. J., et al. (1996). Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. Journal of Rheumatology, 23(6), 995–1000.
Ringe, J. D., Coster, A., Meng, T., Schacht, E., & Umbach, R. (1999). Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium. Calcified Tissue International, 65(4), 337–340.
Eastell, R., Devogelaer, J. P., Peel, N. F., Chines, A. A., Bax, D. E., Sacco-Gibson, N., et al. (2000). Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporosis International, 11(4), 331–337.
Boutsen, Y., Jamart, J., Esselinckx, W., & Devogelaer, J. P. (2001). Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. Journal of Bone and Mineral Research, 16(1), 104–112.
Crandall, C. (2002). Parathyroid hormone for treatment of osteoporosis. Archives of Internal Medicine, 162(20), 2297–2309.
Sambrook, P. N. (2007). Anabolic therapy in glucocorticoid-induced osteoporosis. New England Journal of Medicine, 357(20), 2084–2086.
Bitto, A., Burnett, B. P., Polito, F., Levy, R. M., Marini, H., Di Stefano, V., et al. (2009). Genistein aglycone reverses glucocorticoid-induced osteoporosis and increases bone breaking strength in rats: a comparative study with alendronate. British Journal of Pharmacology, 156(8), 1287–1295.
Xu, D., Yang, W., Zhou, C., Liu, Y., & Xu, B. (2010). Preventive effects of berberine on glucocorticoid-induced osteoporosis in rats. Planta Medica, 76(16), 1809–1813.
Mok, S. K., Chen, W. F., Lai, W. P., Leung, P. C., Wang, X. L., Yao, X. S., et al. (2010). Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. British Journal of Pharmacology, 159(4), 939–949.
Zhang, G., Qin, L., & Shi, Y. (2007). Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial. Journal of Bone and Mineral Research, 22(7), 1072–1079.
Nian, H., Ma, M. H., Nian, S. S., & Xu, L. L. (2009). Antiosteoporotic activity of icariin in ovariectomized rats. Phytomedicine, 16(4), 320–326.
Wang, F. S., Ko, J. Y., Yeh, D. W., Ke, H. C., & Wu, H. L. (2008). Modulation of Dickkopf-1 attenuates glucocorticoid induction of osteoblast apoptosis, adipocytic differentiation, and bone mass loss. Endocrinology, 149(4), 1793–1801.
Gu, G., Hentunen, T. A., Nars, M., Harkonen, P. L., & Vaananen, H. K. (2005). Estrogen protects primary osteocytes against glucocorticoid-induced apoptosis. Apoptosis, 10(3), 583–595.
Yun, S. I., Yoon, H. Y., Jeong, S. Y., & Chung, Y. S. (2009). Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3beta. Journal of Bone and Mineral Metabolism, 27(2), 140–148.
Hsieh, T. P., Sheu, S. Y., Sun, J. S., & Chen, M. H. (2011). Icariin inhibits osteoclast differentiation and bone resorption by suppression of MAPKs/NF-kappaB regulated HIF-1alpha and PGE(2) synthesis. Phytomedicine, 18(2–3), 176–185.
Han, E. H., Kim, H. G., Hwang, Y. P., Song, G. Y., & Jeong, H. G. (2010). Prostaglandin E2 induces CYP1B1 expression via ligand-independent activation of the ERalpha pathway in human breast cancer cells. Toxicological Sciences, 114(2), 204–216.
Zheng, D., Peng, S., Yang, S. H., Shao, Z. W., Yang, C., Feng, Y., et al. (2012). The beneficial effect of Icariin on bone is diminished in osteoprotegerin-deficient mice. Bone, 51(1), 85–92.
Xie, F., Wu, C. F., Lai, W. P., Yang, X. J., Cheung, P. Y., Yao, X. S., et al. (2005). The osteoprotective effect of Herba epimedii (HEP) extract in vivo and in vitro. Evidence-Based Complementary and Alternative Medicine, 2(3), 353–361.
Huang, J., Yuan, L., Wang, X., Zhang, T. L., & Wang, K. (2007). Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sciences, 81(10), 832–840.
Ma, H. P., Ming, L. G., Ge, B. F., Zhai, Y. K., Song, P., Xian, C. J., et al. (2011). Icariin is more potent than genistein in promoting osteoblast differentiation and mineralization in vitro. Journal of Cellular Biochemistry, 112(3), 916–923.
Chen, K. M., Ge, B. F., Liu, X. Y., Ma, P. H., Lu, M. B., Bai, M. H., et al. (2007). Icariin inhibits the osteoclast formation induced by RANKL and macrophage-colony stimulating factor in mouse bone marrow culture. Pharmazie, 62(5), 388–391.
Rochefort, G. Y., Pallu, S., & Benhamou, C. L. (2010). Osteocyte: the unrecognized side of bone tissue. Osteoporosis International, 21(9), 1457–1469.
Robling, A. G., Bellido, T., & Turner, C. H. (2006). Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. The Journal of Musculoskeletal and Neuronal Interactions, 6(4), 354.
Vance, J., Galley, S., Liu, D. F., & Donahue, S. W. (2005). Mechanical stimulation of MC3T3 osteoblastic cells in a bone tissue-engineering bioreactor enhances prostaglandin E2 release. Tissue Engineering, 11(11–12), 1832–1839.
Basso, N., & Heersche, J. N. (2006). Effects of hind limb unloading and reloading on nitric oxide synthase expression and apoptosis of osteocytes and chondrocytes. Bone, 39(4), 807–814.
Meng, L., Cheng, Z., Rong-xin, H., & Li-feng, C. (2012). Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis. Chinese Medical Journal (English Edition), 125(10), 1784–1789.
Seeman, E. (2006). Osteocytes–martyrs for integrity of bone strength. Osteoporosis International, 17(10), 1443–1448.
Ma, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., et al. (2001). Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology, 142(9), 4047–4054.
Noble, B. S., Stevens, H., Loveridge, N., & Reeve, J. (1997). Identification of apoptotic changes in osteocytes in normal and pathological human bone. Bone, 20(3), 273–282.
Tatsumi, S., Ishii, K., Amizuka, N., Li, M., Kobayashi, T., Kohno, K., et al. (2007). Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metabolism, 5(6), 464–475.
Verborgt, O., Gibson, G. J., & Schaffler, M. B. (2000). Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. Journal of Bone and Mineral Research, 15(1), 60–67.
Kogianni, G., Mann, V., & Noble, B. S. (2008). Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localized bone destruction. Journal of Bone and Mineral Research, 23(6), 915–927.
Zand, R. S., Jenkins, D. J., & Diamandis, E. P. (2000). Steroid hormone activity of flavonoids and related compounds. Breast Cancer Research and Treatment, 62(1), 35–49.
Liu, J., Ye, H., & Lou, Y. (2005). Determination of rat urinary metabolites of icariin in vivo and estrogenic activities of its metabolites on MCF-7 cells. Pharmazie, 60(2), 120–125.
Bhargavan, B., Gautam, A. K., Singh, D., Kumar, A., Chaurasia, S., Tyagi, A. M., et al. (2009). Methoxylated isoflavones, cajanin and isoformononetin, have non-estrogenic bone forming effect via differential mitogen activated protein kinase (MAPK) signaling. Journal of Cellular Biochemistry, 108(2), 388–399.
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999). Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. The Journal of Clinical Investigation, 104(10), 1363–1374.
Kousteni, S., Bellido, T., Plotkin, L. I., O’Brien, C. A., Bodenner, D. L., Han, L., et al. (2001). Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell, 104(5), 719–730.
Kousteni, S., Han, L., Chen, J. R., Almeida, M., Plotkin, L. I., Bellido, T., et al. (2003). Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. The Journal of Clinical Investigation, 111(11), 1651–1664.
Chung, B. H., Kim, J. D., Kim, C. K., Kim, J. H., Won, M. H., Lee, H. S., et al. (2008). Icariin stimulates angiogenesis by activating the MEK/ERK- and PI3 K/Akt/eNOS-dependent signal pathways in human endothelial cells. Biochemical and Biophysical Research Communications, 376(2), 404–408.
Pang, W. Y., Wang, X. L., Mok, S. K., Lai, W. P., Chow, H. K., Leung, P. C., et al. (2010). Naringin improves bone properties in ovariectomized mice and exerts oestrogen-like activities in rat osteoblast-like (UMR-106) cells. British Journal of Pharmacology, 159(8), 1693–1703.
This study was supported by the grant from the National Natural Science Foundation of China (81000323) and the Natural Science Foundation of Shandong Province, China (ZR2009CM067).
Rongjie Feng and Li Feng contributed equally to this paper.
About this article
Cite this article
Feng, R., Feng, L., Yuan, Z. et al. Icariin Protects Against Glucocorticoid-Induced Osteoporosis In Vitro and Prevents Glucocorticoid-Induced Osteocyte Apoptosis In Vivo. Cell Biochem Biophys 67, 189–197 (2013). https://doi.org/10.1007/s12013-013-9533-8
- Glucocorticoid-induced osteoporosis
- Osteocyte apoptosis